Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-19
    E.g., 2018-09-19

Archive Search

7 results
1:42 PM, Dec 01, 2017  |  BC Week In Review | Clinical News  |  Clinical Status

Regeneron to discontinue nesvacumab/Eylea combo

data from the trials before deciding on how to proceed with nesvacumab, a mAb against angiopoietin 2
ANG2; ANGPT2). He said Regeneron has not disclosed whether the candidate is in testing for other …
Tarrytown, N.Y.  Bayer AG (Xetra:BAYN), Leverkusen, Germany  Product: Nesvacumab (REGN910, SAR307746)  Business: Cancer  Molecular target: Angiopoietin 2
12:00 AM, Feb 08, 2016  |  BC Week In Review | Clinical News  |  Clinical Status

Anti-VEGF/Ang2 Nanobody: Phase I started

BI 836880 )   Business: Cancer   Molecular target: Vascular endothelial growth factor (VEGF); Angiopoietin 2
ANG2) (ANGPT2)   Description: Bispecific Nanobody targeting VEGF and angiopoietin 2 (ANG2; ANGPT2)   Indication: Treat advanced …
12:00 AM, Feb 11, 2013  |  BC Week In Review | Clinical News  |  Clinical Status

RG7221: Phase I started

patients. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland   Product: RG7221   Business: Cancer   Molecular target: Angiopoietin 2
ANG2) (ANGPT2) ; Vascular endothelial growth factor (VEGF)   Description: Bispecific mAb targeting VEGF and angiopoietin 2
ANG2; ANGPT2)   Indication: Treat solid tumors   Endpoint: Safety   Status: Phase I started   …
12:00 AM, Nov 05, 2012  |  BC Week In Review | Clinical News  |  Clinical Status

REGN910: Phase Ib started

Euronext:SAN; NYSE:SNY), Paris, France   Product: REGN910 , SAR307746   Business: Cancer   Molecular target: Angiopoietin 2
ANG2) (ANGPT2)   Description: Antibody against angiopoietin 2 (ANG2; ANGPT2)   Indication: Treat advanced solid tumors   …
12:00 AM, Jan 30, 2012  |  BC Week In Review | Clinical News  |  Clinical Status

AMG 386: Suspended Phase III enrollment

  Product: AMG 386   Business: Cancer   Molecular target: Angiopoietin 1 (ANG1) (ANGPT1) ; Angiopoietin 2
ANG2) (ANGPT2)   Description: Recombinant Fc-peptide fusion protein (peptibody) targeting angiopoietins   Indication: Treat ovarian cancer …
12:00 AM, Dec 05, 2011  |  BC Week In Review | Clinical News  |  Clinical Status

AKB-9778: Phase I started

Akebia Therapeutics Inc. , Cincinnati, Ohio   Product: AKB-9778   Business: Ophthalmic   Molecular target: Angiopoietin 2
ANG2) (ANGPT2)   Description: Protein tyrosine phosphatase receptor type D ( PTPRD ; HPTP ) beta …
12:00 AM, Jan 31, 2011  |  BC Week In Review | Clinical News  |  Clinical Status

AMG 386: Phase III ongoing

  Product: AMG 386   Business: Cancer   Molecular target: Angiopoietin 1 (ANG1) (ANGPT1) ; Angiopoietin 2
ANG2) (ANGPT2)   Description: Recombinant Fc-peptide fusion protein (peptibody) targeting angiopoietins   Indication: Treat ovarian cancer …